BCM
TXG icon

Bayesian Capital Management’s 10x Genomics TXG Stock Holding History

Bayesian Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,100
Closed -$529K – 1108
2024
Q1 		$529K Sell
14,100
-400
-3% -$17.6K 0.05% 421
2023
Q4 		$811K Buy
14,500
+2,700
+23% +$117K 0.09% 277
2023
Q3 		$487K Sell
11,800
-8,200
-41% -$427K 0.06% 381
2023
Q2 		$1.12M Buy
+20,000
New +$1.08M 0.12% 232
2023
Q1 		– Sell
-13,407
Closed -$489K – 1096
2022
Q4 		$489K Buy
+13,407
New +$438K 0.07% 361

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bayesian Capital Management's TXG Position: Q2 2024 in Review

Bayesian Capital Management sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 14,100 shares — an estimated $529K sold.

Bayesian Capital Management first reported a position in TXG in Q4 2022 and held it in 5 quarters. The position peaked at $1.12M in Q2 2023. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

  • Bayesian Capital Management reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 14,100 10x Genomics shares in Q2 2024, an estimated $529K.
  • Bayesian Capital Management first reported a position in 10x Genomics in Q4 2022 and held it in 5 quarters.
  • Bayesian Capital Management's 10x Genomics position peaked at $1.12M in Q2 2023.
  • 261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.